Literature DB >> 28666564

The dilatation of main pulmonary artery and right ventricle observed by enhanced chest computed tomography predict poor outcome in inoperable chronic thromboembolic pulmonary hypertension.

Ryogo Ema1, Toshihiko Sugiura2, Naoko Kawata2, Nobuhiro Tanabe3, Hajime Kasai2, Rintaro Nishimura3, Takayuki Jujo3, Ayako Shigeta3, Seiichiro Sakao2, Koichiro Tatsumi2.   

Abstract

BACKGROUND: Dilatation of the pulmonary artery and right ventricle on chest computed tomography images is often observed in patients with pulmonary hypertension. The clinical significance of these image findings has not been defined in chronic thromboembolic pulmonary hypertension. We investigated whether the pulmonary arterial and right ventricle dilatation was associated with poor outcome in chronic thromboembolic pulmonary hypertension.
METHODS: This was a retrospective cohort investigation in 60 subjects with inoperable chronic thromboembolic pulmonary hypertension diagnosed consecutively between 1997 and 2010 at Chiba University Hospital. Digital scout multi-detector chest computed tomography images were obtained. The main pulmonary arterial to ascending aortic diameter ratio and the right ventricular to left ventricular diameter ratio were calculated.
RESULTS: Main pulmonary arterial to ascending aortic diameter ratio ranged from 0.85 to 1.84, and right ventricular to left ventricular diameter ratio ranged from 0.71 to 2.88. During the observation period of 1284.5days (range, 21-4550days), 13 patients required hospitalization due to worsening; 6 of them died. Kaplan-Meier analysis showed significant differences in hospitalization between the patients with main pulmonary arterial to ascending aortic diameter ratio of ≥1.1 and <1.1 (log-rank test, p=0.014) and between the patients with right ventricular to left ventricular diameter ratio of ≥1.2 and <1.2 (log-rank test, p=0.013). There was a significant difference in the prognosis between the patients with RV/LV ratio≥1.2 and those with RV/LV ratio<1.2 (log-rank test, p=0.033).
CONCLUSIONS: Main pulmonary arterial to ascending aortic diameter ratio measured using enhanced CT images was associated with the risk for first clinical exacerbation, and right ventricular to left ventricular diameter ratio was associated with the risk for poor prognosis in inoperable chronic thromboembolic pulmonary hypertension.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chest computed tomography; Chronic thromboembolic pulmonary hypertension; Prognosis; Pulmonary artery dilatation; Right ventricular dilatation

Mesh:

Year:  2017        PMID: 28666564     DOI: 10.1016/j.ejrad.2017.06.007

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  Computed tomography angiographic parameters of pulmonary artery as prognostic factors of residual pulmonary hypertension after pulmonary endarterectomy.

Authors:  Matus Niznansky; Jan Kavan; Petra Zemankova; Tomas Prskavec; David Ambroz; Pavel Jansa; Jaroslav Lindner
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 2.  COVID-19: looking beyond the peak. Challenges and tips for radiologists in follow-up of a novel patient cohort.

Authors:  R McStay; A Johnstone; S S Hare; J Jacob; A Nair; J C L Rodrigues; A Edey; G Robinson
Journal:  Clin Radiol       Date:  2020-10-08       Impact factor: 2.350

Review 3.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): A Review of Another Sequel of Severe Post-Covid-19 Pneumonia.

Authors:  Guillermo Cueto-Robledo; Ernesto Roldan-Valadez; Luis-Eugenio Graniel-Palafox; Marisol Garcia-Cesar; Maria-Berenice Torres-Rojas; Rocio Enriquez-Garcia; Hector-Daniel Cueto-Romero; Nathaly Rivera-Sotelo; Angel-Augusto Perez-Calatayud
Journal:  Curr Probl Cardiol       Date:  2022-03-25       Impact factor: 16.464

4.  Commentary: Another tool for the chronic thromboembolic pulmonary hypertension toolbox.

Authors:  Justin C Y Chan; Stephanie H Chang
Journal:  JTCVS Open       Date:  2022-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.